Acquired factor VII (FVII) deficiency in the absence of vitamin K deficiency, oral anticoagulant therapy, synthetic liver dysfunction, or DIC is rare, with only a handful of cases thus far reported. In the period from 1990 to 1996 we identified eight patients with acquired FVII deficiency, all of whom presented with prolongation of the prothrombin time (PT) in the first 2 weeks following stem cell transplantation (SCT). The mean plasma FVII clotting activity (FVII:c) was 22% (range 8-35%) with an approximately equivalent reduction in FVII antigen (FVII:Ag) level. Mean plasma levels of fibrinogen and factors II, V, IX, and X were normal. Protein C activity was significantly depressed in only one of the three patients in whom it was measured. Several patients experienced bleeding complications, and hemorrhage directly accounted for death in two cases. Veno-occlusive disease of the liver developed in three patients. We conclude that FVII deficiency should be considered in the differential diagnosis of prolonged PT in patients who have recently undergone SCT. The mechanism of this acquired deficiency state remains to be defined.
Isolated acquired FVII deficiency in the absence of vitamin K deficiency, coumadin therapy, synthetic liver dysfunction, or overt DIC is rare, having been described in only a handful of cases. Associated disease states have included malignancy, 2 aplastic anemia, 3, 4 and antiphospholipid antibodies. 5, 6 In stem cell transplant (SCT) patients, a modest reduction in FVII levels (in the 25 to 50% range) has been described in the first 2 weeks following SCT. [7] [8] [9] In these cases it has often been associated with deficiencies of other factors such as FXII or protein C. 10 It has been suggested that the fall in FVII and protein C levels in this setting may be a harbinger of veno-occlusive disease of the liver (VOD). 11 Bleeding after SCT has been identified as a significant risk factor affecting outcome. [12] [13] [14] Commonly encountered sites of bleeding include hemorrhagic cystitis, diffuse alveolar hemorrhage, and oro-mucosal and gastro-intestinal sources. Although thrombocytopenia is clearly a major contributing factor, other reasons, such as toxicity related to the preparative regimen, infection, and graft-versus-host disease, have all been cited. Acquired FVII deficiency, at least of the degree previously reported, has not been implicated as a risk factor for hemorrhage following SCT.
In this communication, we describe the clinical and laboratory features of a series of patients with acquired FVII deficiency following SCT, who have been managed at our institution. The frequency and severity of bleeding complications in these patients suggest that this coagulopathy may have contributed to adverse outcomes.
Methods

Patients
We conducted a retrospective chart review of eight patients known to have developed acquired FVII deficiency during SCT at the University of Minnesota between 1990 and 1996. The transplants were carried out using a myeloablative regimen, followed by allogeneic or autologous hematopoietic SCT (using bone marrow or peripheral blood stem cells). Post-transplant care consisted of GVHD prophylaxis, anti-microbial prophylaxis and therapy as needed, nutritional support, and transfusion support with red cell and platelet products. Routine parenteral vitamin K supple-mentation was administered to all patients. Daily blood counts were obtained and coagulation tests were performed if clinically indicated, eg in patients with bleeding, septicemia, or suspected DIC. In non-bleeding patients, platelets were transfused to keep the platelet counts greater than 10-20 ϫ 10 9 /l. Hemoglobin was routinely maintained at Ͼ8.0 G/dl. These parameters were revised upwards for patients with clinically overt bleeding. Coagulopathy was assessed initially by a battery of tests that included prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), Clauss fibrinogen, and fibrin(ogen) degradation product titer. In the event of a clotting time being prolonged, a 1:1 mix with normal plasma was performed to differentiate the presence of a coagulation inhibitor from a factor deficiency. This was followed by specific factor assays if indicated. At the discretion of the attending physician, coagulopathy was treated with fresh frozen plasma (FFP), and/or cryoprecipitate infusions with a therapeutic goal of clinical hemostasis (in the case of clinical bleeding) and/or normalization of laboratory parameters of coagulation. In some cases, additional doses of parenteral vitamin K were also administered. None of the patients were receiving any form of anti-thrombotic therapy nor anti-platelet agents, such as aspirin or non-steroidal anti-inflammatory agents.
Factor assays
Measurement of specific clotting factor activity was in all cases performed by a one-stage clotting assay (PT-based assay for factors II, VII and X, and APTT-based assay for FIX), using a mixture of the appropriate factor-deficient substrate plasma and test plasma. All factor assays were performed at 1/10, 1/20, 1/40, and 1/80 dilutions. The results are expressed as a percentage, with 100% equivalent to the appropriate factor level in pooled plasma samples from 40 normal volunteers. Reference ranges for factor levels were established as the mean Ϯ 2 s.d. of 40 normal individuals. Prior to January 1993, rabbit brain thromboplastin (Thromboplastin C, Dade Laboratories, Deerfield, IL, USA) was used in our laboratory for PT and PT-based factor assays. The stated International Sensitivity Index (ISI) of this reagent was 2.71. Subsequently, all PT assays were performed using recombinant re-lipidated tissue factor (Innovin, Dade) with an ISI of 1.0. APTT was performed using an in-house reagent in which 0.075% aluminum silicate was used as an activator, and the chloroform extract of acetone-dried rabbit brain thromboplastin as the phospholipid source. 15 The immunoreactive level of factor VII antigen was measured using a commercial ELISA kit (Diagnostica Stago, Asnieres, France).
Plasma fibrinogen was assayed by the Clauss method. Protein C activity was assayed using a commercially available kit (COAMATIC Protein C; Chromogenix, Milan, Italy), according to the manufacturer's instructions.
Lupus inhibitor screen
A screening test for lupus inhibitor was performed by performing an APTT on the patient plasma with four different APTT reagents, namely: (1) the in-house aluminum silicate reagent referred to above; (2) APTT-FSL reagent (Sigma Diagnostics, St Louis, MO, USA); (3) Dade Actin FS (Dade-Behring Inc); and (4) Organon Teknika (Durham, NC, USA) automated APTT reagent. When a prolonged APTT was detected with one or more reagents, a 1:1 mix of patient and normal pooled plasma was performed, and the APTT repeated using that same reagent(s). Failure of the mixing study to correct led to the performance of the platelet neutralization procedure 16 (with one or more reagents) to confirm the diagnosis of a lupus inhibitor. After converting our procedure to include the dilute Russell viper venom time (dRVVT), with mix and confirm steps, subsequent to 1996, we were able to determine that the multiple APTT screening approach used in this study was a very specific, if somewhat less sensitive technique for screening for lupus anticoagulants.
FVII antibody screening methods
Two separate methods were used to screen for the presence of an auto-antibody to FVII. Firstly, we used a previously described ELISA method in which patient plasma was screened for the presence of anti-FVII(a) IgG. 17 Reference ranges and cut-off limits were established by screening multiple normal donors. Secondly, in order to screen for a neutralizing antibody to FVII, we used a plasma mixing assay. Specifically, FVII:c was measured in patient and standard (pooled normal) plasma, which were then mixed in equal proportions. FVII:c was assayed both immediately after mixing and following a 1 h incubation at 37°C. A positive result (ie presence of an inhibitory antibody) was suspected if the FVII:c in the mixed sample (either at time zero or after 1 h incubation) was approximately 15% or more below the expected value. This arbitrary cut-off value was chosen taking into account the fact that FVII:c in the mix sample might be slightly less than expected -in the absence of an inhibitor -simply due to the reproducibility of the factor VII assay. In order to minimize artifactual loss of activity of labile clotting factors (such as FVIII) in the mix, a 1 h incubation is routinely used in our laboratory to screen for possible coagulation factor inhibitory antibodies. The exception to this is in the case of suspected FVIII inhibitors, where a 2 h incubation, as described in the original 18 (and subsequently modified 19 ) Bethesda assays, is used.
Statistical analysis
Significance testing of the differences observed between clotting factor levels seen in our patients was performed using a two-tailed, paired Student's t-test, using Microsoft Excel Version 5.0 software. Mean and standard error of mean were calculated using standard methods.
Results
Between 1990 and 1996, during which period 1443 stem cell transplants were performed, eight patients with acquired FVII deficiency of a moderately severe degree were retrospectively identified. These individuals came to our attention because of an unexplained prolongation of the PT, which was usually seen 9-12 days following SCT. Clinical data are summarized in Table 1 . The mean patient age in this series was 33 years (range 10-43). All patients were recipients of bone marrow or peripheral blood SCT for a variety of hematologic disorders or solid tumors. Four patients received an allogeneic sibling transplant, while two received autologous and two received unrelated donor transplants. Five patients underwent conditioning therapy with cytoxan (Cy) and total body irradiation (TBI), one received a regimen of busulfan, Cy, anti-thymocyte globulin and TBI (patient No. 5). The two patients undergoing autologous SCT were conditioned with carboplatin, etoposide and melphalan.
At the time of diagnosis all patients were receiving routine parenteral vitamin K supplements, and did not have apparent DIC or synthetic liver dysfunction. PT prior to SCT was normal in all cases. In the two patients who survived the acute phase of SCT or chemotherapy, recovery to a normal PT was seen coincident with engraftment (patient Nos 3 and 7). In evaluating the cause of the PT prolongation, it was found that FVII:c levels were reduced in all patients, with a mean value of 22% (range 8-35%).
In the cases where FVII:c levels were repeated, from 1 to 6 days later, similarly low values were obtained. Therefore, it is possible that the mean nadir value for FVII:c would have been even lower. In the three patients tested, a close correlation between FVII:c and FVII:Ag levels was noted (not shown), indicating that the reduced FVII:c was not due to synthesis of a dysfunctional FVII molecule, such as could occur with vitamin K deficiency.
The mean plasma FVII:c was significantly decreased compared to mean FII:c (P Ͻ 0.01), FV:c (P Ͻ 0.01), FIX:c (P Ͻ 0.01), and FX:c (P Ͻ 0.01). Fibrinogen levels were also well preserved, remaining within or above the AML ϭ acute myelogenous leukemia; CML ϭ chronic myeloid leukemia; PNH ϭ paroxysmal nocturnal hemoglobinuria; PBSCT ϭ peripheral blood stem cell transplant; URD ϭ unrelated donor; Sib ϭ sibling donor. ND ϭ not done. In all cases, PT was normal at baseline. Reference ranges for individual factors were as follows: fibrinogen (factor I) ϭ 170-370 mg/dl; factors II, V, VII, X, and protein C ϭ 70-130%; factor IX ϭ 75-135%.
Bone Marrow Transplantation normal reference range in all patients (Table 1) . Notably also, when measured more than once over a period of a week or more, the levels of these factors remained stable, without any progressive decline, suggesting that there was not a generalized loss of hepatic clotting factor synthetic activity. Protein C chromogenic activities (performed on the same samples as FVII levels shown in Table 1) were obtained in three patients; the level was borderline in two and frankly low in patient No. 2 (P ϭ 0.3). Like factor VII, protein C has a relatively short half-life in plasma, and any pathophysiologic mechanism affecting factor VII levels (such as proteolysis, enhanced clearance, or biosynthesis) might also be reflected in reduced protein C levels. However, despite the fact that protein C was measured in only three individuals, the results tend to suggest a relatively more selective decrease in factor VII.
Six patients were screened for the presence of a lupus inhibitor, either because of a mild prolongation of the APTT, or because of a clinical suspicion that the PT prolongation and/or low FVII:c might be due to an associated inhibitor. Four were found to be positive. In two patients with a positive lupus inhibitor study, an IgG and IgM anticardiolipin antibody screen was negative. Nevertheless, the presence of these lupus anticoagulants raised the possibilities that (1) PT prolongation was also due to a lupus anticoagulant, or (2) that there existed an associated autoantibody to FVII; analogous auto-antibodies to other vitamin K-dependent coagulation factors that are capable of binding to phospholipid have been described in association with lupus anticoagulants. 20 With respect to the former possibility, a PT mixing study was performed in two patients (Nos 6 and 8), demonstrating full correction in both cases. Furthermore, FVII:c assays were performed at several dilutions in all patients, with no observed difference in the measured FVII level, suggesting that there was no 
a Mixing study in which PT (rather than FVII levels) was measured.
artifactual dimunition of the factor VII level due to a circulating inhibitor. With respect to the possibility of a neutralizing FVII-specific inhibitor, we were unable to detect any significant change in FVII:c levels after a 1 h incubation of a mix of normal and patient plasma from three individuals (Nos 3, 4, 5) with acquired FVII deficiency. Furthermore, the possibility of either a neutralizing or non-neutralizing inhibitor to FVII in three patients (Nos 1, 2, 3) is essentially excluded by the negative findings with a validated ELISA which detects IgG antibodies directed to FVII(a) ( Table 2 ). The overall clinical outcome in this group of patients was dismal, with six patients dying within the first month following SCT (Table 3) . Bleeding complications were frequent in this group of patients (Table 3) and directly accounted for two deaths (from gastrointestinal and pulmonary hemorrhage, in patients 6 and 8, respectively). These events occurred despite aggressive platelet and FFP replacement therapy. FVII levels did not appear to improve as expected immediately after large volume FFP infusions in two patients, one of whom is illustrated in Figure 1 . In one other patient (No. 3), a plasma exchange approximately equivalent to a single plasma volume (3.5 l), using fresh frozen plasma as the replacement fluid, was performed prior to debridement of the maxillary sinuses for invasive fungal sinusitis. The incremental rise in plasma FVII:c level was much less than anticipated (11% pre-exchange, rising to only 19% immediately following the procedure). As a result, the planned surgery was deferred. There was a grad- Previous studies suggested that a fall in FVII levels in SCT patients is a predictor of VOD of the liver; in this series, three patients (Nos 3, 4 and 6) developed clinical features of this complication. Their mean FVII:c level (17%) was not significantly different when compared to the other five patients (mean ϭ 25%).
Discussion
We present clinical data from a retrospective series of eight patients who developed a coagulopathy characterized by a low plasma FVII level with essentially normal levels of other coagulation factors following myelo-ablative chemotherapy and SCT. Because of the rather severe reduction in FVII:c levels, this may represent a distinct clinical entity. Despite the usually benign course of inherited FVII deficiency of an equivalent degree, FVII deficiency after SCT appears to have a tendency to be accompanied by a variably severe hemorrhagic diathesis that was directly responsible for the death of two patients, and was a contributing factor to death in two others. The defect was uniformly refractory to parenteral vitamin K supplementation, to massive FFP infusion (in two patients) and, in one case, to plasma exchange with FFP replacement. However, we would like to emphasize the fact that this case series is a retrospective review based on clinical observations made over a long period of time. Due to possible recall bias, and conceivably because of a tendency to under-diagnose this condition without routine PT checks (which were not performed), we cannot estimate the true incidence of this syndrome following SCT. Indeed, after the recognition of this clinical entity, one other patient undergoing induction chemotherapy for AML was diagnosed with acquired FVII deficiency (FVII:c 18%) with normal levels of other coagulation factors and protein C. His clinical course was complicated by epistaxis and gastrointestinal bleeding requiring transfusion support. However, his prothrombin time normalized upon entering remission, with recovery of his blood counts. Therefore, this syndrome may not be limited to SCT alone, but rather may also affect patients undergoing intensive chemotherapy.
Some previous studies, 11 but not others, 21 have concluded that a falling FVII level following SCT is a harbinger of VOD of the liver. In this series, three of the eight patients in our series did, in fact, develop clinical findings of VOD. While this is a significant proportion of the total, it is also clear that VOD is not inevitably associated with acquired FVII deficiency. It has been previously noted that in chronic liver disease, FVII levels may be particularly low when compared to factors II and X. 22 We cannot, therefore, fully exclude the possibility that the acquired and seemingly selective FVII deficiency that we observed is simply a manifestation of liver dysfunction, whether due to VOD or some other etiology. Overall, however, several clinical features point to the possibility of accelerated clearance rather than synthetic dysfunction as the mechanism for FVII deficiency. Specifically, these include: (1) the lack of response in FVII levels to seemingly adequate replacement therapy with FFP in several patients, and a full plasma exchange in one other; and (2) the preservation of other factor levels in plasma on repeated follow-up.
In the cases of isolated acquired FVII deficiency that have been described previously, an inhibitory antibody to FVII has been described in only a few instances. In occasional cases, 5, 6 ,23 a neutralizing auto-antibody could be demonstrated in vitro. The reasonably frequent finding of a lupus inhibitor in our patients further heightened the possibility that FVII deficiency may have been due to development of an associated auto-antibody to FVII. 5 The observation that new lupus inhibitors may develop after SCT has been previously reported from this institution. 24 However, having failed to demonstrate a neutralizing antibody to FVII by mixing experiments, we used ELISA to Bone Marrow Transplantation search for auto-antibodies to FVII(a). Such antibodies might not be detected by mixing experiments, yet they could remain capable of accelerating clearance of FVII/anti-FVII immune complexes. This was an attractive hypothesis given the previous demonstration of this mechanism in another patient with acquired FVII deficiency. 4 However, in three patients who were screened by ELISA none had a detectable titer of antibody to FVII(a). Although our ELISA actually utilized immobilized FVIIa (which may differ conformationally from native FVII) to capture circulating immunoglobulin, we suspect that this did not compromise our ability to detect an antibody to zymogen FVII.
The apparent lack of evidence for an auto-immune mechanism does not preclude other possible reasons for accelerated FVII clearance. An acquired form of FVII deficiency very similar to that described herein has been noted in patients with sepsis, in whom the proposed mechanism was cleavage of FVII by granulocyte-derived proteases. 25 Furthermore, a similar unexplained fall in plasma FVII:c (and FVIIa) levels has been observed following the administration of endotoxin to normal volunteers. 26 In the absence of a clearly defined mechanism, one can speculate about an alternative explanation for the apparent loss of FVII, namely enhanced binding to its principal ligand, tissue factor (TF). TF is a cell-associated trans-membrane glycoprotein that is predominantly, 27 although not exclusively, 28 localized to cells in the extravascular compartment in vivo.
We speculate that high-dose chemo-radiotherapy, by inducing a state of increased vascular permeability, enhances access of intravascular FVII to a large pool of extravascular TF, sequestering FVII in the extra vascular compartment. However, proof of this hypothesis would require carefully designed FVII clearance studies in vivo.
We observed severe hemorrhagic complications in several of our patients, which in some cases contributed directly to their demise. It is difficult to know to what extent acquired FVII deficiency may have contributed to these complications, especially since congenital FVII deficiency at levels of 10-15% is generally not associated with a bleeding tendency. 29 However, it may be that lesions that might otherwise have posed a minor hemostatic challenge to an intact coagulation system, bleed catastrophically in the presence of both sub-optimal circulating FVII levels and thrombocytopenia following SCT. Replacement therapy with FFP and platelets failed to improve FVII:c levels or achieve hemostasis in several of our cases. Novel therapies such as rFVIIa, perhaps combined with antifibrinolytic agents, may result in improved outcomes, particularly in view of recent data documenting the efficacy of rFVIIa in both FVII-deficient and thrombocytopenic patients. [30] [31] [32] In conclusion, we describe an uncommon form of acquired coagulopathy arising as a complication of highdose chemotherapy and SCT, which contributed to the early demise of several patients undergoing this therapy. Further studies are needed to clearly elucidate the mechanism of this coagulopathy and whether patients with associated bleeding might be candidates for therapy with novel hemostatic agents.
